Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TOVX Theriva Biologics Inc
- Stocks
- Healthcare
- NYSEAMERICAN: TOVX
Price (delayed)
$0.43
Market cap
$3.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$13.67
Enterprise value
-$3.74M
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's
Highlights
Theriva Biologics's EPS has soared by 53% YoY and by 28% from the previous quarter
The net income has decreased by 30% YoY but it has increased by 3.3% QoQ
The debt has soared by 82% since the previous quarter and by 41% year-on-year
The quick ratio has plunged by 59% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of TOVX
Market
Valuations
Earnings
Shares outstanding
8.19M
Market cap
$3.52M
Enterprise value
-$3.74M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$25.37M
Net income
-$24.81M
EBIT
-$24.81M
EBITDA
-$24.23M
Free cash flow
-$16.81M
Per share
Balance sheet
Liquidity
EPS
-$13.67
EPS diluted
-$13.67
Free cash flow per share
-$6.04
Book value per share
$5.57
Revenue per share
$0
TBVPS
$11.56
Total assets
$32.16M
Total liabilities
$16.66M
Debt
$2.86M
Equity
$15.5M
Working capital
$4.33M
Debt to equity
0.18
Current ratio
1.53
Quick ratio
1.24
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-66.2%
Return on equity
-116.6%
Return on invested capital
-138.6%
Return on capital employed
-103.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TOVX stock price
How has the Theriva Biologics stock price performed over time
Intraday
-2.32%
1 week
-0.53%
1 month
0%
1 year
-92.93%
YTD
-75.43%
QTD
-60.91%
Financial performance
How have Theriva Biologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.37M
Net income
-$24.81M
Gross margin
N/A
Net margin
N/A
The net income has decreased by 30% YoY but it has increased by 3.3% QoQ
The company's operating income fell by 17% YoY but it rose by 3.7% QoQ
Price vs fundamentals
How does TOVX's price correlate with its fundamentals
Growth
What is Theriva Biologics's growth rate over time
Valuation
What is Theriva Biologics stock price valuation
P/E
N/A
P/B
0.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Theriva Biologics's EPS has soared by 53% YoY and by 28% from the previous quarter
TOVX's P/B is 80% below its 5-year quarterly average of 0.4 and 60% below its last 4 quarters average of 0.2
TOVX's equity has plunged by 51% YoY and by 19% from the previous quarter
Efficiency
How efficient is Theriva Biologics business performance
The ROE has shrunk by 137% YoY and by 15% QoQ
The ROA has plunged by 101% YoY and by 7% from the previous quarter
The return on invested capital has declined by 35% year-on-year and by 2.2% since the previous quarter
Dividends
What is TOVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TOVX.
Financial health
How did Theriva Biologics financials performed over time
The total assets is 93% more than the total liabilities
The quick ratio has plunged by 59% YoY and by 19% from the previous quarter
Theriva Biologics's current ratio has plunged by 58% YoY and by 29% from the previous quarter
The debt is 82% smaller than the equity
The debt to equity has soared by 200% YoY and by 125% from the previous quarter
The debt has soared by 82% since the previous quarter and by 41% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.